|
PFDN1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.33109975766865E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.07080000422144E-09 |
| Normal-vs-Stage2 |
3.241200E-03 |
| Normal-vs-Stage3 |
3.71750000005555E-07 |
| Normal-vs-Stage4 |
4.38940000013766E-07 |
| Stage1-vs-Stage2 |
4.256400E-01 |
| Stage1-vs-Stage3 |
7.916600E-01 |
| Stage1-vs-Stage4 |
6.338200E-01 |
| Stage2-vs-Stage3 |
5.759200E-01 |
| Stage2-vs-Stage4 |
3.140400E-01 |
| Stage3-vs-Stage4 |
5.117600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.78730030775398E-10 |
| Normal-vs-AfricanAmerican |
2.015400E-04 |
| Normal-vs-Asian |
1.1228999999835E-06 |
| Caucasian-vs-AfricanAmerican |
7.860200E-01 |
| Caucasian-vs-Asian |
5.149600E-01 |
| AfricanAmerican-vs-Asian |
4.765600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.03659999473038E-08 |
| Normal-vs-Female |
1.40790001879054E-09 |
| Male-vs-Female |
4.118600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.79359996141682E-10 |
| Normal-vs-Age(41-60Yrs) |
3.46139999995998E-08 |
| Normal-vs-Age(61-80Yrs) |
1.582140E-04 |
| Normal-vs-Age(81-100Yrs) |
6.243800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.805800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.601600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.517410E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.417830E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.359900E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.020290E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.018240E-01 |
| Classical-VS-Follicular |
4.15250001051248E-09 |
| Classical-VS-Other |
9.311800E-01 |
| Classical-VS-Normal |
2.64277488781772E-12 |
| Tall-VS-Follicular |
3.12120000001137E-06 |
| Tall-VS-Other |
5.335000E-01 |
| Tall-VS-Normal |
3.13849999988847E-07 |
| Follicular-VS-Other |
6.311900E-02 |
| Follicular-VS-Normal |
2.347000E-01 |
| Other-VS-Normal |
8.951900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.54249999999978E-05 |
| Normal-vs-N1 |
4.184300000043E-06 |
| N0-vs-N1 |
3.449800E-02 |
|
|
